Search
Vicasinabin
go.drugbank.com/drugs/DB21587InvestigationalVicasinabin is under investigation in clinical trial NCT04265261 (A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic … Vicasinabin has a monoisotopic molecular weight of 358.2 Da.
PX-12
go.drugbank.com/drugs/DB05448InvestigationalSince high levels of Trx-1 have been associated with colorectal, gastric and lung cancers, PX-12 is indicated as a potential cancer treatment in combination with chemotherapy for patients with advanced … PX-12 (1-methylpropyl 2-imidazolyl disulfide) is a small-molecule inhibitor of Trx-1 (thioredoxin-1), stimulates apoptosis, down-regulates HIF-1α and vascular endothelial growth factor (VEGF) and inhibits
SYNB1353
go.drugbank.com/drugs/DB17666InvestigationalSYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered probiotic drug. … [A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria.
Desmethylprodine
go.drugbank.com/drugs/DB01478ExperimentalIllicitIt has been listed as a Schedule I controlled drug in the United States, and thus is not used clinically. It is known to be a designer drug, synthesized in 1977, for the purpose of recreational use. … Desmethylprodine, a derivative of meperidine, is an opioid analgesic with the potency of morphine.
Canfosfamide
go.drugbank.com/drugs/DB04972InvestigationalCanfosfamide is an active agent in chemotherapy-resistant ovarian cancer.
Fabomotizole
go.drugbank.com/drugs/DB13623InvestigationalCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesBenzilone
go.drugbank.com/drugs/DB13369ExperimentalCategories: Drugs for Functional Gastrointestinal DisordersQuisovalimab
go.drugbank.com/drugs/DB16482InvestigationalCategories: Experimental Unapproved Treatments for COVID-19Amubarvimab
go.drugbank.com/drugs/DB16493InvestigationalAmubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.
Categories: Experimental Unapproved Treatments for COVID-19